Fig. 3: Low SENP6 expression is associated with aggressive tumor biology.

a Results of SENP6 copy number analysis of human DLBCL cell lines derived from cancer cell line encyclopedia (top) and experimental workflow for SENP6 reconstitution (bottom). b Analysis of SENP6 protein expression and cell proliferation upon SENP6 reconstitution versus empty vector (EV) transduced control cells (n = 3 independent experiments). Data are presented as mean ± SD. P-value determined by unpaired t-test (two-tailed). c Flow cytometry analysis of cell death of the cell lines described in b using propidium iodide staining (n = 4 independent experiments). Data are presented as mean ± SD. P-value determined by unpaired t-test (two-tailed). d GSEA of expression data derived from transcriptome profiling of the cell lines described in b with the indicated gene set. e Representative immunohistochemical stainings of human DLBCL cases with SENP6 low (score 0) and high SENP6 expression (score 3), magnification ×200, insert ×400. SENP6 analysis revealed an association between SENP6 expression levels (high versus low) and clinical outcome (remission > 2 years, n = 37 versus early relapse/refractory <1 year, n = 38). P-value determined by Fisher’s exact test (two-sided). f Viability of indicated cell lines after 48 h treatment with the indicated concentrations of doxorubicin relative to control. Viability is determined by propidium iodide staining and flow cytometry measurement. P-value determined by two-way ANOVA; Bonferroni’s multiple comparisons test. Data are presented as mean ± SD from three independent experiments.